Lv2
118 积分 2026-01-27 加入
Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison
4个月前
已关闭
Glucose‐lowering drugs and liver‐related outcomes among individuals with type 2 diabetes: A systematic review of longitudinal population‐based studies
4个月前
已完结
Liver gains beyond glycemic control: GLP-1 vs. SGLT2 in metabolic dysfunction–associated steatohepatitis (MASH): A real-world data analysis
5个月前
已关闭
Effects of sodium-glucose contrasporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on arterial stiffness, coronary flow reserve and liver steatosis in diabetes
5个月前
已完结
Comparative effectiveness of GLP ‐1 receptor agonists, SGLT2 inhibitors and DPP ‐4 inhibitors on liver outcomes in metabolic dysfunction‐associated steatotic liver disease: A retrospective cohort study
5个月前
已完结
Comparative effectiveness of GLP ‐1 receptor agonists, SGLT2 inhibitors and DPP ‐4 inhibitors on liver outcomes in metabolic dysfunction‐associated steatotic liver disease: A retrospective cohort study
5个月前
已完结
S2463 Targeting Liver and Glucose: Comparative Efficacy of SGLT2i and GLP-1RA in NAFLD Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis
5个月前
已关闭
Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes
5个月前
已关闭
Hepatic events associated with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a nationwide cohort study
5个月前
已完结
Glucagon‐Like Peptide‐1 Receptor Agonists and Liver Outcomes in Patients With MASLD and Type 2 Diabetes
5个月前
已完结
皖公网安备34019202002308
